OncoMatch/Clinical Trials/NCT07228832
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Is NCT07228832 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Drug: Ivonescimab and Drug: Bevacizumab for metastatic colorectal cancer (crc).
Treatment: Drug: Ivonescimab · Drug: Bevacizumab — A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Excluded: BRAF v600e
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy
Cannot have received: anti-angiogenic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Study Site · Goodyear, Arizona
- Clinical Study Site · Beverly Hills, California
- Clinical Study Site · Cerritos, California
- Clinical Study Site · Corona, California
- Clinical Study Site · Duarte, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07228832 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with BRAF alterations eligible?
No. BRAF v600e is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages